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https://doi.org/10.1053/j.gastro.2018.03.034BACKGROUND & AIMS: Hirschsprung disease (HSCR) is an
inherited congenital disorder characterized by absence of
enteric ganglia in the distal part of the gut. Variants in ret
proto-oncogene (RET) have been associated with up to 50% of
familial and 35% of sporadic cases. We searched for variants
that affect disease risk in a large, multigenerational family with
history of HSCR in a linkage region previously associated with
the disease (4q31.3–q32.3) and exome wide. METHODS: We
performed exome sequencing analyses of a family in the
Netherlands with 5 members diagnosed with HSCR and 2
members diagnosed with functional constipation. We initially
focused on variants in genes located in 4q31.3–q32.3; however,
we also performed an exome-wide analysis in which known
HSCR or HSCR-associated gene variants predicted to be dele-
terious were prioritized for further analysis. Candidate genes
were expressed in HEK293, COS-7, and Neuro-2a cells and
analyzed by luciferase and immunoblot assays. Morpholinos
were designed to target exons of candidate genes and injected
into 1-cell stage zebraﬁsh embryos. Embryos were allowed to
develop and stained for enteric neurons. RESULTS: Within the
linkage region, we identiﬁed 1 putative splice variant in the
lipopolysaccharide responsive beige-like anchor protein gene
(LRBA). Functional assays could not conﬁrm its predicted effect
on messenger RNA splicing or on expression of the mab-21 like
2 gene (MAB21L2), which is embedded in LRBA. Zebraﬁsh that
developed following injection of the lrba morpholino had a
shortened body axis and subtle gut morphological defects, but
no signiﬁcant reduction in number of enteric neurons
compared with controls. Outside the linkage region, members
of 1 branch of the family carried a previously unidentiﬁed RET
variant or an in-frame deletion in the glial cell line derived
neurotrophic factor gene (GDNF), which encodes a ligand of
RET. This deletion was located 6 base pairs before the last
codon. We also found variants in the Indian hedgehog gene
(IHH) and its mediator, the transcription factor GLI family zinc
ﬁnger 3 (GLI3). When expressed in cells, the RET-P399L variant
disrupted protein glycosylation and had altered phosphoryla-
tion following activation by GDNF. The deletion in GDNF pre-
vented secretion of its gene product, reducing RET activation,
and the IHH-Q51K variant reduced expression of the tran-
scription factor GLI1. Injection of morpholinos that targetihh reduced the number of enteric neurons to 13% ± 1.4% of
control zebraﬁsh. CONCLUSIONS: In a study of a large family
with history of HSCR, we identiﬁed variants in LRBA, RET, the
gene encoding the RET ligand (GDNF), IHH, and a gene
encoding a mediator of IHH signaling (GLI3). These variants
altered functions of the gene products when expressed in cells
and knockout of ihh reduced the number of enteric neurons in
the zebraﬁsh gut.Keywords: ENS; Neural Development; Genetic Causes of HSCR;
Family Study.
irschsprung disease (HSCR) is a congenital disorderHcharacterized by the absence of enteric ganglia in
variable lengths of the distal gut. As a consequence, func-
tional networks of neurons and glia, the intrinsic in-
nervations of the gastrointestinal tract comprising the
enteric nervous system (ENS), cannot be established,1
leading to intestinal obstruction by dysregulated smooth
muscle contraction/relaxation.
HSCR is considered to be an inherited disease. This
assumption is based on several lines of evidence, including
familial occurrence (w5%), elevated risk of occurrence in
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Hirschsprung disease (HSCR) arises due to failure of the
enteric neurons to colonize the gut. It is an inherited
disorder, but the genetic cause is unknown in the
majority of cases.
NEW FINDINGS
In a Dutch multigenerational family with history of HSCR,
the authors identiﬁed variants in RET, GDNF, IHH and
GLI3 that disrupt the function of their encoded proteins,
contributing to disease development.
LIMITATIONS
The variants identiﬁed in this family are rare and unlikely to
explain the missing heritability seen in the majority of
HSCR cases.
IMPACT
This study conﬁrms RET as the major HSCR gene and
shows that a combination of rare variants in GDNF, IHH
and GLI3, modulates clinical expression of the disease
phenotype.
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chromosomal abnormalities, and the existence of many
naturally occurring animal models with colonic aganglio-
nosis.2 The mode of inheritance can vary from dominant
with reduced penetrance, mostly found in nonsyndromic
familial HSCR cases, to recessive, in families with syn-
dromic HSCR.2 Sporadic HSCR cases also have been re-
ported and are believed to be multifactorial and polygenic
in nature, suggesting the involvement of several genes in
concert.
The search for genes involved in HSCR has been exten-
sive and ranged from classical linkage to genome-wide as-
sociation studies and candidate gene approaches. To date,
mutations in approximately 20 genes have been identiﬁed.3–5
However, the REarranged during Transfection (RET) gene
is still considered to be the major HSCR gene, as 50% of
familial cases and 15% to 35% of sporadic cases carry a
mutation in its coding or messenger RNA (mRNA) splicing
regions. The RET locus (10q11) was the ﬁrst one to be
identiﬁed for HSCR,6 and, subsequently, coding variants in
this gene were reported to give rise to a dominant form of
the disease with incomplete penetrance (72% for male and
51% for female individuals).7–10 Moreover, all association
studies conducted on sporadic HSCR cases showed the
highest association with a low-penetrant variant present in
intron 1 of RET (odds ratio ¼ 2 when heterozygous and odds
ratio ¼ 20 when homozygous).11,12 Taken together, these
genetic ﬁndings showed that RET variants can be high- or
low-penetrant, but more importantly, they demonstrated
that almost every patients with HSCR has a variant in RET.
Thus, RET seems to be crucial in developing HSCR, but it is
also likely that one or more modiﬁer genes, as well as envi-
ronmental factors, are involved in disease pathogenesis,
even when a high penetrant RET mutation is found.13,14
Linkage analysis conducted on 12 multiplex HSCR familiescorroborated this idea. Although 11 families showed linkage
to the RET locus, only half of them (6) carried a severe RET
coding mutation.14 Intriguingly, the remaining 5 families also
showed linkage to 9q31, suggesting the involvement of a
modiﬁer gene at this locus.15 After these early ﬁndings,
subsequent studies were conducted to search for modiﬁer
loci in HSCR. Sib-pair analysis resulted in the identiﬁcation
of 2 additional loci at 3p21 and 19q12,16 haplotype sharing
in a large Mennonite kindred identiﬁed a new locus
on 16q23,17 linkage analysis in a multigenerational Dutch
family identiﬁed a locus at 4q31.3-q32.3,18 and genome-
wide association studies also have identiﬁed loci at
7q21.11 and 8p12.5,19 However, combinations of distinct
rare mutations resulting in HSCR are not frequently
reported.4,20–22
In this article, we focus on one family in which a 12.2-
Mb interval suggestive for linkage was identiﬁed on
4q31.3-q32.3 (chr4: 142,197,646–158,353,484 [Hg19]),
but no pathogenic variants in the known HSCR genes have
been found.18 Based on the pedigree, incomplete pene-
trance of a disease-associated variant was expected, sug-
gesting the involvement of several genes. In an attempt to
identify the genetic cause of HSCR in this family, we have
now used whole-exome sequencing to search for yet un-
identiﬁed pathogenic rare variants or modiﬁer genes. We
determined segregation patterns for candidate variants,
and performed in vitro and in vivo studies to test the
involvement of the identiﬁed candidate genes in disease
pathogenesis, revealing the complex genetic nature of
HSCR.
Materials and Methods
Patient Information
A multigenerational Dutch family was included in this
study. This family is composed of 5 individuals diagnosed with
HSCR (IV-3, V-1, V-2, V-3, and V-4), and 2 diagnosed with
functional constipation (III-1 and IV-2) (Figure 1). A detailed
description of the phenotypes has been previously reported.18
Written informed consent was obtained from the parents for
diagnostic analysis.Exome Sequencing and Variant Prioritization
Two HSCR-affected individuals (V-1 and V-4) from different
branches of the family were initially selected for exome
sequencing. In a later stage of the study, IV-4 and IV-5 were
also included (Figure 1). Three micrograms of DNA from each
of the individuals was used. Details about execution and data
analysis can be found in supplementary data.Validation of Candidate Variants and Family
Screening
Genomic DNA was isolated from peripheral blood leuco-
cytes using a standard protocol previously described.23 Candi-
date variants were validated by Sanger sequencing as
previously described.24 Segregation analysis was performed
using family members for which DNA was available (II-2, III-2,
IV-1, IV-2, IV-3, IV-4, IV-5, V-1, V-2, V-3, and V-4).
Figure 1. Pedigree of the
multigenerational Dutch
family. Subjects affected
with HSCR are repre-
sented as black symbols
(IV-3, V-1, V-2, V-3, and
V-4), and those affected
with constipation are
marked in gray (III-1 and
IV-2). Individuals submit-
ted to whole-exome
sequencing are marked
with arrows. Segregation
analysis was performed,
and the presence (þ) or
absence () of variants
located in the identiﬁed
candidate genes is also
represented.
120 Sribudiani et al Gastroenterology Vol. 155, No. 1
BASIC
AND
TRANSLATIONAL
ATVector Design and Site Direct Mutagenesis
Vectors used are described in detail in supplementary data.
Whole-Mount In Situ Hybridization for lrba,
mab21l2, and ihh in Zebraﬁsh
lrba (lipopolysaccharide responsive beige-like anchor),
mab21l2 (Mab-21-Like 2), and ihh (Indian hedgehog) genes
were ampliﬁed from total mRNA collected from zebraﬁsh em-
bryos at 48 hours post fertilization (hpf), by reverse tran-
scription polymerase chain reaction (RT-PCR) using a One-Step
RT-PCR Kit (Qiagen, Valencia, CA). Primers used are described
in Supplementary Table 1. A detailed protocol can be found in
supplementary data.
lrba, mab21l2, and ihh Morphant Analysis in
Zebraﬁsh
Two splice blocking morpholinos were designed to target
exon 13 (AGTTGGTTTAGTCTCTTACCGAGAC) and exon 24
(ACTGCATACTAACCGAAGAAGAAGT) of lrba. The effectiveness
of these morpholinos was conﬁrmed by RT-PCR. A previously
described translation blocking morpholino for mab21l2
(ACTGTAGACCGGAGTTTCGCAGTAC) was used25 (Gene Tools,
Philomath, OR). A mab21l2 mutant line (au12 allele) was also
analyzed.26 The ihh morpholino (GGAGACGCATTCCACCGCA
AGCG) was designed to target the transcription start site of ihh,
as previously described.27 Morphants were generated by
injecting 100 mM of each morpholino into 1-cell-stage zebraﬁsh
embryos. Morphant/mutant and control embryos were allowed
to develop until 120 hpf and were ﬁxed and stained for ENS
neurons using the HuC/D antibody (Invitrogen, Carlsbad, CA),
as previously reported.28 A p53 control morpholino
(Gene Tools) was coinjected in all morphant and controlembryos, to suppress apoptotic effects induced as a secondary
effect of the morpholinos, as described elsewhere.29 To deter-
mine the number of enteric neurons present, a 10-segment
length of the gut to the vent was counted. The numbers in
the text represent percent of control ± SEM for at least 5
separate embryos per morpholino/mutant genotype. Signiﬁ-
cance was determined by the Student t test with signiﬁcance
assessed when P < .0005.
Cell Culture and Transfections
Human embryonic kidney (HEK293) cells, COS-7 cells (CV-1
[simian] in origin, and carrying the SV40 genetic material), and
control ﬁbroblasts were cultured in Dulbecco’s modiﬁed Eagle’s
minimal essential medium (GIBCO, Waltham, MA) containing
10% fetal bovine serum (GIBCO) and penicillin/streptomycin
(GIBCO). The neuroblastoma cell line (Neuro-2a) (CCL-131;
American Type Culture Collection, Manassas, VA) was cultured
according to the protocol of the American Type Culture
Collection. All cell lines were incubated at 37oC, and supplied
with 5% CO2. Transfection was performed as described
before.30
Exon Trap Assays
The exon trap assays were performed as described
before.31,32 SD6 and SA2 primers are described in
Supplementary Table 1.
Luciferase Assays
Neuro-2a cells were transfected with 1 mg of SV40-P or
LRBA-wild-type (WT)/mutant (Mut) vectors and cotransfected
with 10 ng of internal control, pRL-SV40-Renilla Luciferase
(Promega, Madison, WI). Luciferase activity was measured and
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moter) was used as a negative control and RET-WT-enhancer
was used as a positive control.33 Luciferase assays were per-
formed in 3 independent, triplicate experiments (n ¼ 9).
Activation of the Indian Hedgehog Signaling
HEK293 cells cultured in a 6-well plate were transiently
transfected with pCMV-IHH-FLAG-WT/Mut. After 24 hours, the
medium of transfected cells (conditioned medium) was
collected and ﬁltered using a 0.45-mm ﬁlter; 200,000 to
300,000 control human ﬁbroblast cells were cultured in a
6-well plate for 24 hours. After this period, the medium was
replaced by 1 mL fresh complete medium and 500 mL condi-
tioned medium (containing secreted IHH-WT or IHH-Mut).
Conditioned medium derived from nontransfected HEK293
cells was used as a negative control. Medium supplemented
with 20 mM Purmophamine (Calbiochem, San Diego, CA) was
used as a positive control for activation of the Hedgehog (Hh)
signaling; 500 mL conditioned medium was concentrated using
an M-10 ﬁlter (Millipore, Bedford, MA) and used for Western
blot to determine the levels of IHH-WT and IHH-Mut protein
secreted into the medium.
Glial Cell–Derived Neurotrophic Factor
Stimulation and Western Blot
HEK293 cells were transiently cotransfected with pCMV-
RET-WT/Mut (P399L), pCMV-GFRa1, and pNE–green ﬂuores-
cent protein (GFP). After 24 hours, cells were treated with 50
ng/mL glial cell–derived neurotrophic factor (GDNF) (Pepro-
Tech EC, London, UK) for 15 minutes. To test the effect of the
GDNF deletion, conditioned medium collected from HEK293
cells transfected with a GDNF-WT or GDNF-Mut constructs was
collected in a similar way as described for IHH, and used to
stimulate HEK293 cells transfected with pCMV-RET-WT, pCMV-
GFRa1, and pNE-GFP. An amount of 500 mL of conditioned
medium was also concentrated as described for IHH, and used
to determine the levels of GDNF-WT and GDNF-Mut protein
secreted into the medium by Western blot. Cell lysis, protein
quantiﬁcation, and Western blot were performed as previously
described.30 Primary and secondary antibodies used are
described in Supplementary Table 2.
RNA Isolation and qReal-time-PCR
RNA isolation, complementary DNA preparation, and
quantitative real-time (qRT) PCR are described in
supplementary data.
Statistical Analysis
All results are expressed as the mean ± standard deviation
or standard error of the mean. All data were analyzed using a
2-tailed Student t test or the c2 test. P < .05 was considered to
be statistically signiﬁcant.
Results
A Putative Splice Variant in LRBA Was Found in
the Linkage Interval
Exome sequencing data collected from patients V-1 and
V-4 were ﬁrst analyzed to detect variants present in thelinkage interval previously identiﬁed.18 Exons that were not
totally covered within this region (7 exons), were Sanger
sequenced. From the exome analysis, only 1 rare variant
(Exome Aggregation Consortium: 0.002534, and Genome of
the Netherlands database: 0.009), predicted to be delete-
rious was found: a putative splice variant affecting exon 20
of the LRBA gene (NM_001199282.2:c.2444A>G) (Table 1
and Supplementary Table 3). LRBA was also found to be
expressed in mouse gut,34 leading us to consider it the best
candidate gene for this family. Sanger sequencing conﬁrmed
the presence of the LRBA variant in all family members for
which DNA was available (n ¼ 11), and segregation patterns
were determined (Figure 1; Supplementary Table 4).
lrba Is Not Required for ENS Development in
Zebraﬁsh
To investigate a possible role for LRBA in ENS develop-
ment, we used the zebraﬁsh as a model system. A single
zebraﬁsh ortholog for lrba was identiﬁed in an Ensemble
gene search, which showed strong sequence similarity, as
well as genome organization, to its human ortholog (82%
homology). Whole-mount in situ hybridization revealed that
lrba has a comparatively restricted expression pattern in
zebraﬁsh (Figure 2A). At 24 hpf, lrba expression was identi-
ﬁed along the yolk sac boundary andweakly in the hindbrain.
At 48 hpf, lrba was still weakly present in the hindbrain, and
no apparent expression was detected elsewhere in the em-
bryo (Figure 2A). A similar pattern of expression was detec-
ted at 72 and 96 hpf. However, at 72 hpf, lrba expression
appeared in the intestinal bulb, and it was maintained at 96
hpf (Figure 2A). We also designed 2 different splice blocking
morpholinos to suppress expression of this gene in zebraﬁsh.
Examination of lrba morphants at 120 hpf revealed a short-
ened body axis and subtle gut morphological defects. How-
ever, no signiﬁcant reduction in the number of enteric
neurons was detected when compared with controls, as the
number of neurons in lrba morphants was 97.2% ± 4.8% of
control (n ¼ 17; Figure 2B).
Lack of Splicing Effect and Enhancing Defects for
the LRBA Variant
The LRBA variant identiﬁed in this family
(NM_001199282.2:c.2444A>G) is predicted to affect mRNA
splicing of exon 20 by 1 of the 5 splice site prediction
programs included in the Alamut splicing prediction module
(http://www.interactive-biosoftware.com/alamut-visual/).
To conﬁrm pathogenicity of this variant, exon trap assays
were performed, but no splice defect was detected. Similar-
size bands of spliced product were observed in both the WT
and Mut situations (Figure 3A).
Within intron 42 of LRBA, another gene called Mab-21-
Like 2 (MAB21L2) is found (Figure 3B). A previous study
has shown that expression of MAB21L2 can be controlled in
a tissue-speciﬁc manner by several enhancer elements
present within LRBA.35 This led us to hypothesize that exon
20 of LRBA might work as one of these enhancers, and that
the variant identiﬁed in this gene might disturb expression
of MAB21L2. Because the role of MAB21L2 in ENS
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sion pattern of this gene in zebraﬁsh, by performing whole-
mount in situ hybridization at different stages of embryonic
development. mab21l2 was already known to be strongly
expressed in the hindbrain and cranial neural crest in
zebraﬁsh.25 Our results conﬁrmed this expression pattern,
and revealed strong expression of this gene in the pharyn-
geal arches, especially at 48 hpf (Supplementary Figure 1).
We also observed a signiﬁcant expression of mab21l2 in the
gut mesoderm from 48 hpf onward, which has not been
reported before (Supplementary Figure 1). To investigate
the importance of MAB21L2 for ENS development, we
initially used a morpholino-based approach to knock down
this gene in zebraﬁsh. Subsequently, we obtained a mab21l2
mutant line (au12 allele).26 Morphant and mutant ﬁsh had
identical phenotypes with defects in development of
pharyngeal arches and intestinal smooth muscle, as previ-
ously reported.25 Critically, we detected a signiﬁcant
reduction in the number of enteric neurons in mab21l2
homozygous mutants, which was 28.2% ± 3.8% of that seen
in WT siblings (n ¼ 12; Figure 3C). These results led us to
conclude that mab21l2 is required for ENS development in
zebraﬁsh, and that it might therefore also contribute to
HSCR pathogenesis in humans. To further explore this
possibility, we investigated whether the LRBA variant found
in this family acts as a prospective enhancer element,
thereby affecting MAB21L2 expression. For this, a series of
luciferase assays was performed using exon 20 of LRBA and
its ﬂanking regions, containing the WT or the Mut sequence
(c.2444A>G). Our results showed that exon 20 of LRBA
could indeed enhance the promoter activity of SV40
(Figure 3D). However, no difference was detected when the
LRBA variant (c.2444A>G) was introduced (Figure 3D).
Considering this result, we were unable to link MAB21L2 to
HSCR, as it is unlikely that the LRBA variant identiﬁed has an
enhancing effect. However, to rule out the possibility that a
mutation in MAB21L2 was missed in the exome analysis, we
Sanger sequenced all exons of MAB21L2 and its regulatory
regions (16 Kb upstream), in patients V-1 and V-4. No rare
variants were identiﬁed that could be associated to the
disease phenotype.
Variants in RET, IHH, GLI3, and GDNF Were
Detected Outside the Linkage Interval
As we were unable to conﬁrm pathogenicity of the
variant found in LRBA, and could not ﬁnd a link between
MAB21L2 and HSCR pathogenesis, we hypothesized that
variants outside the linkage interval would be the ones
determining disease development. Therefore, we focused on
nonshared rare variants outside the linkage interval present
in any of the 2 individuals sequenced (V-1 and V-4). A de
novo analysis was also performed using the trio composed
of IV-4, IV-5, and V-4. Initially, these 2 analyses aimed to
ﬁnd variants present in genes previously associated with
HSCR.3,4 Moreover, variants were prioritized based on
function and deleteriousness. With this approach, we
found a previously unidentiﬁed rare variant in RET
(NM_020975.4:c.1196C>T; p.P399L) in patient V-1 (Table 1
and Supplementary Table 3). Segregation analysis showed
Figure 2. lrba is expressed in the gut but it is not required for ENS development in zebraﬁsh. (A) In situ hybridization performed
in zebraﬁsh embryos showed the expression pattern of lrba during embryonic development. At 24 hpf, lrba is present along the
yolk sack and is weakly expressed in the hindbrain. This pattern of expression is detected throughout all time points analyzed.
From 72 hpf, a strong signal is detected in the intestinal bulb (arrows). (B) HuC/Elavl3 staining showed that the distribution and
number of enteric neurons along the gut in lrba morphants is similar to controls.
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unaffected mother (IV-2), and the affected maternal uncle
(IV-3) also carry the same heterozygous RET variant,
whereas the grandmother (III-2) does not (Figure 1,
Supplementary Table 4). Due to DNA unavailability, we
were unable to conﬁrm the presence of this variant in the
grandfather (III-1). However, considering that both the
mother (IV-2) and the grandfather (III-1) were reported to
suffer from severe constipation in childhood, and the
grandmother (III-2) had no intestinal complains, it is likely
that this RET variant was inherited from the grandfather
(III-1). For patient V-4, 2 rare variants were identiﬁed
in 2 different genes: Indian hedgehog (IHH)
(NM_002181.3:c.151C>A; p.Q51K), and the GLI family zinc
ﬁnger 3 (GLI3) (NM_000168.5:c.2119C>T; p.P707S)
(Table 1 and Supplementary Table 3). Segregation analysis
showed that both variants were inherited from the father
(Figure 1, Supplementary Table 4). The de novo analysis
performed for patient V-4 also identiﬁed a heterozygous in-
frame deletion in the Glial cell–derived neurotrophic factor
gene (GDNF) (NM_001190468.1:c.676_681delGGA TGT)
(Figure 1, Table 1). No allelic frequencies of any of these
variants were found in the available databases.
RET-P399L Disturbs Protein Glycosylation and
Affects Phosphorylation on GDNF Activation
In Vitro
To determine the effect of the RET rare variant identiﬁed
in the ﬁrst branch of the family (c.1196C>T, p.P399L), we
examined the glycosylation and phosphorylation status of
the mutant protein and compared it with the WT. As
expected, 2 bands were identiﬁed in the presence of the
RET-WT–expressing vector (Figure 4A). The lower band(w150 kDa) corresponds to the unglycosylated RET pro-
tein, whereas the upper one (w170 kDa) is the glycosylated
(mature) RET protein. In the presence of the RET-Mut (RET-
P399L) expressing vector, only the lower band was detec-
ted, suggesting that this variant disturbs protein glycosyla-
tion (Figure 4A). RET phosphorylation was also investigated
on GDNF stimulation, and in the presence of the Mut-
expressing vector, RET phosphorylation was dramatically
reduced (Figure 4A). These results conﬁrm pathogenicity of
the RET variant identiﬁed.IHH-Q51K Disturbs Activation of Hedgehog
Signaling In Vitro
To study the effect of the IHH variant identiﬁed in patient
V-4 (c.151C>A, p.Q51K), we transiently transfected HEK293
cells with IHH-WT-FLAG and IHH-Q51K-FLAG vectors.
Comparative expression levels of the precursor form of IHH-
WT (w46 kDa) and IHH-Q51K were found in the cell lysates
and in the conditioned medium from transfected HEK293
cells (Figure 4B). However, a signiﬁcant lower expression of
the transcriptional target of Hh signaling, GLI1, was identi-
ﬁed by qreal time-PCR in ﬁbroblasts cultured in the pres-
ence of conditioned medium containing the secreted form of
mutant IHH (Figure 4C). This result conﬁrms pathogenicity
of the IHH variant identiﬁed.ihh Is Required for ENS Development in Zebraﬁsh
Transgenic zebraﬁsh embryos Tg(-8.3phox2b:Kaede)
were injected with a morpholino designed to speciﬁcally
target expression of ihh to further study the involvement of
this gene in ENS development. Morphant and uninjected
control embryos were visualized at 120 hpf and several
Figure 3. The LRBA variant identiﬁed does not affect splicing nor its enhancing ability, and is likely not involved in the
regulation of MAB21L2 expression. (A) Exon trap assay showed that splicing of exon 20 of LRBA is not affected by the
presence of the variant identiﬁed (c.2444A>G), as similar-size bands were obtained for WT and Mut constructs. E, empty
vector; M, 1Kbþ DNA marker (Invitrogen); Un, untransfected cells. (B) Schematic overview of the genomic region of LRBA with
MAB21L2 as a nested pair (located in intron 42 of LRBA), and their respective positions in the human genome (hg19). The
variant in exon 20 of LRBA is located 288.6 Kb away from the start site ofMAB21L2. (C) Immunohistochemistry performed with
an HuC/Elavl3 antibody in control and mab21l2 mutant zebraﬁsh embryos, showed that the absence of mab21l2 leads to an
overall reduction in the numbers of enteric neurons, and aganglionosis is detected in the gut. (D) Luciferase assays performed
to evaluate a possible enhancer effect of the LRBA variant (c.2444A>G) showed that although exon 20 has enhancer activity
when coupled to an SV40 promoter (SV40-P), no difference in luciferase activity could be detected between LRBA WT and
LRBA Mut (c.2444A>G) constructs. SV40-E construct was used as a negative control, and a RET intronic enhancer element
(RET-WT) was used as a positive control.
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curved body, small eyes, and no swim bladder (Figure 4D).
Moreover, a signiﬁcant decrease in the number of enteric
neurons was detected when compared with controls
(Figure 4D). The number of enteric neurons in ihh mor-
phants was 13% ± 1.4% of that seen in controls (n ¼ 23),
suggesting that ihh is required for normal ENS development
in zebraﬁsh.De Novo Deletion in GDNF Leads to Reduced
Levels of Secreted Protein and Results in
Impaired RET Activation
A heterozygous de novo in-frame deletion in GDNF was
identiﬁed in patient V-4 (NM_001190468.1:c.676–681delG-
GATGT). Because this deletion affects 6 base pairs (bp)
located just before the last codon of GDNF, a change in RNAstability is expected based on the RNAfold online software
(http://rna.tbi.univie.ac.at/cgibin/RNAfold.cgi; Supplementary
Figure 2 and Supplementary Table 5). To evaluate this
effect, we performed qreal time-PCR on RNA isolated from
HEK293 cells transfected with GDNF-WT-Myc-DDK and
GDNF-Mut-Myc-DDK–expressing constructs. No signiﬁcant
effect on the mRNA levels was observed in the presence of
the deletion (Figure 5A). To determine if the in-frame
deletion identiﬁed impairs the function of GDNF, HEK293
cells transiently expressing RET and GFR-a1, were treated
with conditioned medium containing GDNF-WT-Myc-DDK
and GDNF-Mut-Myc-DDK. We observed that in the pres-
ence of the mutant protein, a decrease in RET expression
and phosphorylation levels was observed when compared
with the WT. This suggests that the deletion identiﬁed does
affect the ability of GDNF to activate RET (Figure 5B).
Moreover, we observed that the GDNF-Mut protein was
Figure 4. Variants in RET and IHH have a pathogenic nature. (A) Western blot analysis of HEK293 cells transiently expressing
pCMV-RET-WT and pCMV-RET-Mut showed that the RET variant identiﬁed (c. 1196C>T, p.RET-P399L), leads to a reduction
of glycosylated protein, as well as a reduction in the levels of phosphorylated RET. b-actin was used as loading control and
GFP as transfecting control. (þ) presence and () absence of GDNF (50 ng/mL). UT, untransfected. (B) Western blot analysis of
HEK293 cells transiently expressing IHH-WT-FLAG and IHH-Q51K-FLAG showed no difference in the expression of IHH
precursor (w46 kDa). (C) qreal time-PCR performed in ﬁbroblasts grown in the presence of conditioned medium containing
IHH-WT or IHH-Q51K secreted proteins, showed that cells stimulated with the mutant IHH have reduced expression of GLI1
when compared with cells stimulated with the WT protein. Purmorphamine (PURþ), an activator of the Hh signaling, was used
as a positive control. (D) Analysis of the uninjected control and ihh morphant embryos at 120 hpf showed that the absence of
ihh led to curvature of the body, smaller eyes, craniofacial abnormalities, and a loss of swim bladder. Moreover, a decreased
number of enteric neurons was observed in morphant embryos after staining with an Elavl3-speciﬁc antibody. * marks the anus
of the ﬁsh.
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still present inside the cells. The opposite situation was
detected for GDNF-WT (Figure 5C). Based on our results, we
concluded that the 6-bp deletion impairs secretion of GDNF,
thus resulting in less RET activation.
Discussion
A complete understanding of the genetics of an inheri-
ted complex disease is a major challenge requiring sub-
stantial efforts. In this study, we used a combination of
whole-exome sequencing and functional assays to ﬁnd
the underlying causes of HSCR in a multigenerational Dutch
family.
Multiple Variants Contribute to HSCR
Finding multiple contributing variants seems logical for
a disease with reduced penetrance, such as HSCR. There-
fore, we were not surprised to ﬁnd that 4 different genes
appear to modulate disease expression in this family. In the
ﬁrst branch, a missense variant in RET was identiﬁed
(Figure 1). This variant (c.1196C>T, p.P399L), was pre-
dicted to affect the extracellular domain of RET and resultin RET dysfunction. Our in vitro studies conﬁrmed this
prediction, and showed that the variant identiﬁed was
pathogenic, as it affected glycosylation and phosphoryla-
tion of RET (Figure 4A). A previous study of this family also
reported that all 3 affected siblings (V-1, V-2, and V-3)
inherited a common heterozygous RET risk haplotype from
their father (IV-1).18 This haplotype is located in intron 1
of RET and has been shown to increase susceptibility for
HSCR36 by affecting RET expression.33,37 Considering that
the mother (IV-2) does not have HSCR despite carrying the
pathogenic RET variant (c.1196C>T, p.P399L), it is logical
to consider that the presence of the risk haplotype
enhanced the penetrance of the RET variant, contributing
to the development of the disease in patients V-1, V-2, and
V-3.
In the second branch of this family, 2 missense variants
located in IHH (NM_002181.3:c.151C>A) and GLI3
(NM_000168.5:c.2119C>T; p.P707S), and 1 de novo dele-
tion in GDNF (c.676–681delGGATGT), have been found to
underlie HSCR pathogenesis in patient V-4 (Figure 1). IHH
and GLI3 encode members of the Hh pathway, whereas
GDNF encodes a RET ligand. Hh signaling is known to be
essential for the development of a variety of tissues and
Figure 5. De novo deletion in GDNF affects protein secretion and RET activation. (A) qreal time-PCR performed using RNA
isolated from HEK293 cells transfected with GDNF-WT and GDNF-Mut constructs, shows that the 6-bp deletion identiﬁed has
no effect on the levels of RNA present. (B) Western blot performed in HEK293 cells transiently expressing RET-WT, GFR-a1,
and GFP, and grown in conditioned medium containing GDNF-WT and GDNF-Mut, showed that cells stimulated with the
mutant GDNF have reduced levels of phosphorylated RET when compared with cells stimulated with the WT protein.
Conditioned medium collected from untransfected HEK293 cells was used as negative control. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as loading control and GFP as transfecting control. (B) Western blot analysis of HEK293
cells transiently expressing GDNF-WT-Myc and GDNF-Mut-Myc showed impaired secretion of the mutant protein (w30
kDa). , absence of GDNF.
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zebraﬁsh.38 Despite a previous suspicion of the involvement
of IHH in HSCR,39 the Hh signaling was only recently linked
to this disease, when mutations in the GLI family of tran-
scription factors, known as effectors of Hh signaling, were
found in a series of patients with HSCR.40 Our functional
studies support this involvement, as they conﬁrmed the
pathogenic nature of the IHH variant identiﬁed (Figure 4C),
and showed that the absence of ihh in zebraﬁsh leads to an
HSCR-like phenotype (Figure 4D). The same effect has been
previously observed in mice. However, only 50% of Ihh
knockout mice showed aganglionosis, suggesting that
depletion of this gene is not fully penetrant, and disruption
of additional genes is required for the intestinal phenotype
observed.41 To date, it is still unclear how IHH affects ENS
development, and further studies are required to determine
if intestinal aganglionosis is due to a failure of migration of
enteric neural crest cells from the vagal neural crest region
into and along the gut tube, or whether IHH is required for
proliferation of enteric neural crest cells once they enter the
gastrointestinal tract. For GLI3, we found that the variant
identiﬁed in patient V-4 and her father (c.2119C>T;
p.P707S) has also been reported in patients with Greig
cephalopolysyndactyly syndrome (MIM 175700), a rare
disorder characterized by craniofacial abnormalities, poly-
dactyly, and syndactyly of hands and feet.42 Previous studies
have shown that this variant is pathogenic, as it leads to
abnormal subcellular localization of GLI3 and reducedtranscriptional activity.43 However, neither IV-4 nor V-4
have any of the features seen in patients with Greig ceph-
alopolysyndactyly syndrome,18,44 leading us to conclude
that this is a low-penetrance variant, likely requiring addi-
tional factors to modulate disease expression. Finally, a de
novo variant in GDNF was also identiﬁed comprising an in-
frame 6-bp deletion that led to the loss of 2 amino acids
(c.676–681delGGATGT). Our results showed that this dele-
tion has a pathogenic effect, as it impairs GDNF secretion
and leads to reduced RET activation (Figure 5B and 5C).
Mutations in GDNF have been previously reported in a few
HSCR cases.20,21 However, it has been postulated that they
are not sufﬁcient to cause HSCR on their own, and require
additional contributing factors.20,21,45 In this particular case,
we hypothesize that the variants identiﬁed in IHH and GLI3
are these additional factors, especially because they are
found in a heterozygote state in this family. Previously, we
have proposed a model for disturbed ENS development, in
which harmful and protective factors balance on a fulcrum
representing a disease-speciﬁc genetic predisposition.14 In
this model, mild variants that are harmless by themselves
can lead to a disease phenotype if found together. For pa-
tient V-4, we believe that the deletion in GDNF is the one
predisposing for HSCR, as it is the only variant present
exclusively in patient V-4 and not in her healthy father (IV-
4). However, it is the additive effect of the variants identiﬁed
in IHH and GLI3 that triggers HSCR development in this
patient.
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Based on the previously performed linkage analysis,18
we were expecting to ﬁnd the causative gene for HSCR in
this family on chromosome 4. Therefore, we initially
focused our efforts on LRBA, as this was the only gene in
the linkage region that showed expression in mouse gut.34
Our functional studies failed to conﬁrm a direct involve-
ment of LRBA in HSCR pathogenesis, and could not support
a direct role for lrba in ENS development in zebraﬁsh
(Figures 2 and 3). Within LRBA, another gene can be found,
MAB21L2, speciﬁcally located in intron 42 of LRBA.
MAB21L2 is known to play a role in neural development,
and here we show that this gene is required for ENS
development in zebraﬁsh (Figure 3C). Based on this evi-
dence, MAB21L2 was considered to be a possible candidate
gene for HSCR in this family, but because we could not
identify any pathogenic variant in this gene in any of the
affected members, and failed to show an effect of the LRBA
variant identiﬁed on MAB21L2 expression, we were unable
to link MAB21L2 to HSCR. Therefore, although we believe
that MAB21L2 could play a role in HSCR pathogenesisFigure 6. Schematic representation of the knbased on its function, the risk allele on chromosome 4 for
this family cannot be attributed to MAB21L2 or LRBA, and
remains to be identiﬁed.
Consequences for Genetic Counseling
Complex inheritance in families with variable expres-
sion and incomplete penetrance is to be expected in HSCR.
However, searching for multiple variants that in concert
can explain disease variation and penetrance within such
families is rare. Common practice in diagnostic labora-
tories is to search for mutations in the major known
disease-associated gene. For HSCR, this means screening
the RET gene. If a mutation is identiﬁed, the search for
additional causing genes stops. However, in some families,
this may not represent the full genetic etiology of the
disease, leading to a miscalculation of the real genetic risk.
Using the family described in this study as an example, the
extensive genetic analysis was performed only because the
RET variant (c.1196C>T, p.P399L) was missed in the
initial screening.46 One could argue that for the branch in
which this variant was found, the additional screen hardlyown and the newly identiﬁed HSCR genes.
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most of the penetrance. However, in the RET negative
branch, the additional genetic screening proved to be
necessary. Finding a de novo GDNF deletion, in combina-
tion with 2 inherited variants in members of the Hh
pathway (IHH and GLI3), changed genetic counseling, as
we now predict a low recurrence risk for this branch of the
family. Based on our ﬁndings, we believe that an extensive
genetic screen can change genetic counseling of a complex
genetic disease, especially if a de novo search is added.
However, one should be cautious to counsel based only on
the presence of a de novo variant, because it is difﬁcult to
assess the contribution of such variants to the overall
disease risk.Conclusions
HSCR is a complex disorder in which several genes are
known to play a role (Figure 6). Although in 20% of the
cases the genetic cause relies on the presence of a single
deleterious mutation in a speciﬁc gene,45 for most patients it
is likely that rare mutations affecting more than 1 gene are
involved in disease pathogenesis. In this study, we report
such a family, in which mutations in members of the major
disease-associated pathway, RET and GDNF, in combination
with mutations in GLI3 and in a previously unrelated HSCR
gene, IHH, are likely to modulate the clinical expression of
the disease phenotype (Figure 6). In addition, our results
show that even familial cases can have a high genetic
complexity, something that should be taken into account
when counseling and performing genetic tests for disorders
with a presumed multifactorial etiology.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
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Supplementary Material and Methods
Exome Sequencing and Variant Prioritization
Three micrograms of DNA from each of the individuals
was sheared using acoustic technology (Covaris, Inc,
Woburn, MA). Target enrichment for V-1 and V-4 was per-
formed with the SureSelect Human All Exon 50 Mb Targeted
exome enrichment kit v4, and for the trio (IV-4, IV-5, and
V-4) the Agilent Sureselect CRE capture kit (Agilent Tech-
nologies, Inc., Santa Clara, CA) was used. Captured frag-
ments were sequenced (paired-end 101-bp read length)
on the Illumina HiSeq2000 (Sureselect V4) and HiSeq2500
(CRE) sequencers (Illumina, San Diego, CA). De-multiplexing,
alignment to the human genome build 19 (Hg19) reference
genome, and curation of low-quality reads were done as
described by our in-house developed NARWHAL pipeline.1
BAM-ﬁles were generated with SAMtools version 0.1.12a,2
and variant calling was performed with the Bayesian
genotyper incorporated in the genome analysis toolkit
version 1.2.9.3 Variant ﬁles generated of VCFv4 format were
uploaded into Cartagenia Bench NGS version 5.0 (Cartagenia
Inc, Boston, MA) for ﬁltering with previously described
settings.4
Vector Design and Site Direct Mutagenesis
The genomic region of LRBA containing exon 20 and its
ﬂanking sequence (approximately 400 bp), was ampliﬁed
from control and patient DNA to obtain WT and Mut
(NM_001199282.2:c.2444A>G) alleles, respectively, using
primers described in Supplementary Table 1 (LRBAF and
LRBAR). PCR products obtained, LRBA-Enh-WT and LRBA-
Enh-Mut, were inserted into the pCR 2.1-TOPO vector,
subsequently digested with XhoI and KpnI restriction en-
zymes, and cloned into a pGL3-SV40 promoter (SV40-P)
upstream of the luciferase gene (Promega, Madison, WI), to
generate the pGL3-SV40p-Luc-LRBA-Enh-WT and pGL3-
SV40p-Luc-LRBA-Enh-Mut vectors. The same LRBA PCR
products, LRBA-Enh-WT and LRBA-Enh-Mut, were also
directly cloned into the exon trapping vector pSPL3 (Invi-
trogen, Carlsbad, CA) to generate the pSPL3-LRBA-WT and
the pSPL3-LRBA-Mut vectors. The pRc/CMV-RET-WT vec-
tor,5 encoding the short isoform of human RET (RET9), was
used to create the pRc/CMV-RET-Mut (P399L) by site-
directed mutagenesis, according to the manufacturer’s in-
structions (Stratagene, La Jolla, CA). The pCMV-IHH-FLAG-
WT vector6 and pCMV6-Entry-GDNF-Myc-DDK vector (Ori-
gene, Rockville, MD) were used to create pCMV-IHH-FLAG-
Mut (Q51K) and pCMV6-Entry-GDNF-Mut (Gly226_-
Cys227del)-Myc-DDK, respectively, by site-directed muta-
genesis, according to the manufacturer’s instructions
(Stratagene and New England Biolabs, Ipswich, MA). All
inserts were Sanger-sequenced to conﬁrm the presence of
the WT and Mut variants, as well as the orientation of the
inserted fragments. Primers used (RET-MutF; RET-MutR;
IHH-MutF, IHH-MutR, GDNF-MutF, and GDNF-MutR) are
described in Supplementary Table 1.
Whole-Mount In Situ Hybridization for lrba,
mab21l2, and ihh in Zebraﬁsh
lrba, mab21l2, and ihh genes were ampliﬁed from total
mRNA collected from zebraﬁsh embryos by RT-PCR.
Ampliﬁed bands were gel-puriﬁed and sub-cloned into
TOPO TA PCRII vector (Thermo Fisher, Waltham, MA).
Digoxigenin-labeled antisense probes (Roche, Basel,
Switzerland) were generated using SP6 polymerase (Roche)
after linearizing the plasmid templates using NotI restriction
enzyme (New England Biolabs). Embryos were collected
and processed for whole-mount in situ hybridization as
previously described.7 Digoxigenin-labeled probes were
visualized with NBT/BCIP coloration reactions.
RNA Isolation and qReal time-PCR
RNA isolation was performed with the RNeasy mini kit
(Qiagen, Valencia, CA) according to the manufacturer’s in-
structions. cDNA preparation was done with the iScrip
cDNA synthesis kit (Bio-Rad, Hercules, CA), using 1 mg RNA
isolated from ﬁbroblasts treated with Purmophamine and
conditioned medium containing IHH-WT and IHH-Mut.
GLI1 expression levels were determined by quantitative
real-time (qreal-time) Sybr Green PCR, using the 7300
Real-time PCR platform system (Applied Biosystems, Fos-
ter City, CA). The same procedure was used to determine
levels of GDNF in HEK293 cells transfected with GDNF-WT
and GDNF-Mut vectors. CLK2 was used as a housekeeping
gene to normalize GLI1 expression levels, while GAPDH and
ACTB were used for GDNF (primer details in
Supplementary Table 1). qreal time-PCR data were
analyzed using a method previously described,8 and pre-
sented as fold changes. These assays were performed in 3
independent triplicates (n ¼ 9).
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Supplementary Figure 1.mab21l2 expression pattern in zebraﬁsh. In situ hybridization showing that mab21l2 has a strong
expression in the hindbrain (black arrows) and pharyngeal arches (white arrows) through all time points (24–96 hpf). From 48
hpf onward, a strong expression is also detected in the gut mesoderm (*).
Supplementary Figure 2. A decrease in RNA stability is
predicted in the presence of the de novo deletion in GDNF, by
in silico analysis. Secondary structures of GDNF WT and Mut
RNA determined using RNAfold software, showed that a
change in both the minimum free energy (MFE) and the
centroid secondary structures are predicted to occur in the
presence of the deletion identiﬁed (arrowheads). Each color
indicates the probability of individual nucleotides to partici-
pate in the structure, and range from the highest (red) to the
lowest probability (blue-violet).
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Supplementary Table 1.List of Primers Used in This Study
Gene Primer (5ʹ–3ʹ)
LRBAF CCACATAACTTAAGGTTGATTC
LRBAR GATATAAGGAGATGTGGCTG
RETF CTGGCCAGCCCATCTTGG
RETR CCGAGTCACCATATGCAGATTTACC
IHHF ATCAGCCCACCAGGAGACC
IHHR CATCAGCCCACCAGGAGACC
GLI3F AGTGGCCAGCTCCATTCACC
GLI3R GGTTACAGCGTCATTTTAGGACTGG
GDNFF TTTCAAACCCTAATGCACTTTTATTCC
GDNFR TGACCTGGAAAAGGCCAAGG
RET-MutF CGTGTCGGTGCTGCTGGTCAGCCTGCAC
RET-MutR GTGCAGGCTGACCAGCAGCACCGACACG
IHH-MutF CGCTCGCCTACAAGAAGTTCAGCCCCAATG
IHH-MutR CATTGGGGCTGAACTTCTTGTAGGCGAGCG
GDNF-MutF ATCACGCGTACGCGGCCG
GDNF-MutR ACACCTTTTAGCGGAATGCTTTCTTAGAATATGG
SD6 TCTGAGTCACCTGGACAACC
SA2 ATCTCAGTGGTATTTGTGAGC
lrbaF CTTTTGACCAAAGGAATGGGTTACG
lrbaR TCCAAGCATGACTTCTGCTTTCC
ihhF GAATTTTACGCACGGACGAT
ihhR CGTAATGCAGCGAATCTTCA
mab21l2F ATTCGCTCCCGCTTTCAG
mab21l2R TCGTCCCAGTCAGTCTCCC
GLI1qF TCCCCATGACTCTGCCCG
GLI1qR CCAGCATGTCCAGCTCAGA
GDNFqF CGCTGAGCAGTGACTCAAAT
GDNFqR AGGAAGCACTGCCATTTGTT
CLK2qF TCGTTAGCACCTTAGGAGAGG
CLK2qR TGATCTTCAGGGCAACTCG
ACTBqF AACCGCGAGAAGATGACCC
ACTBqR GCCAGAGGCGTACAGGGATAG
GAPDHqF CGACCTTCACCTTCCCCAT
GAPDHqR TAAAAGCAGCCCTGGTGACC
Supplementary Table 2.List of Antibodies Used for Western
Blot
Antibodies Host Dilution
RET Rabbit 1:1000
p-RET Rabbit 1:1000
Myc Mouse 1:1000
b-Actin Mouse 1:1000
GAPDH Mouse 1:10,000
GFP Rabbit 1:2000
Flag Mouse 1:1000
IRDDye 800 Goat 1:10,000
IRDDye 680 Goat 1:10,000
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Supplementary Table 3. In Silico Prediction of the Pathogenic Nature of the Rare Variants Identiﬁed in Patients V-1 (a) and V-4 (b)
Sample Gene Variant
PHAST
score
GERPþþ
neutral rate
PhyloP
score
SiPhy
score
Mutation
Taster
SIFT
score
PolyPhen2
HumVar
LRT
prediction
Mutation
Assessor
FATHMM
score BLOSUM62
Cadd Phred
score
a RET c.1196C>T - 5.13 1.151 10.524 1 0 0.856 Deleterious 1.955 3.02 3 27.5
a, b NRP2 c.1000C>T 0.9 5.91 1.505 15.056 1 0.02 0.929 Deleterious 2.555 4.81 3 35
a, b PGRMC2 c.185G>A - 3.81 0.927 7.764 0.734 1 0.003 Neutral 0.345 1.13 2 22.6
a, b LRBA c.2444A>G 1 5.66 0.96 12.981 1 0.01 0.488 Deleterious 2.455 0.12 1 25.2
a, b OR1F1 c.47G>A 1 4.97 2.456 16.064 0.94 0.01 0.997 Deleterious 3.54 5.95 2 23.7
a, b CLUH c.3547G>C 1 5.07 1.248 6.899 0.529 0.08 0.008 Neutral 0.625 1.58 1 21.7
a,b PELP1 c.2696T>C 1 4.42 -0.564 0.625 1 64 0 Neutral 1.5 0.92 0 5.925
a,b PELP1 c.2161A>G 1 5.13 -0.013 3.9 1 21 0 Neutral 0.345 0.93 1 0.144
b IHH c.151C>A - 4.22 2.18 12.671 1 0 0.965 Deleterious 3.56 6.03 1 25.2
b GLI3 c.2119C>T 1 5.82 1.468 14.65 1 0.01 0.925 Neutral 2.865 2.18 1 28.8
b GDNF c.676_
681delGGATGT
- - - - - - - - - - - 20.5
NOTE. The following thresholds were used to evaluate conservation: PhyloP  0.95; GERPþþ  2; SiPhy  5; PHAST conservation score  0; Grantham distance  60. To
predict deleteriousness the following thresholds were used: Mutationtaster  0.51; Pph2 hvar  0.909 (complex disease) or Pph2 hdiv  0.956 (Mendelian disease);
Mutation assessor  1.91; FATHM  -1.50; SIFT  0.049; LRT: deleterious; BLOSUM62  0; CADD Phred  20 (mutations in the splice interval can have lower values).
BLOSUM, Blocks Substitution Matrix; GERP, Genomic Evolutionary Rate Proﬁling; LRT, likelihood ratio test; PolyPhen, Polymorphism Phenotyping v2.
-, unknown.
July
2018
M
utations
in
RET
and
IHH
Pathw
ays
Cause
HSCR
129.e4
Supplementary Table 4.Segregation Analysis of Candidate Variants Identiﬁed by Exome Sequencing in the Family Members
Gene II-2 III-2 IV-1 IV-2 IV-3 IV-4 IV-5 V-1 V-2 V-3 V-4
LRBA (c.2444A>G) þ þ  þ þ þ  þ þ þ þ
RET (c.1196C>T)    þ þ   þ þ þ 
IHH (c.151C>A)      þ     þ
GLI3 (c.2119C>T) NI NI   NI þ   NI NI þ
þ, present; , absent; NI, not investigated.
Supplementary Table 5.Differences in Minimum Free
Energies and Ensemble Diversity of
Predicted Secondary Structures of
GDNF WT and Mut RNA
GDNF WT GDNF Mut
Minimum free energy 192.80 kcal/mol 18.,40 kcal/mol
Free energy of
thermodynamic ensemble
202.,30 kcal/mol 197.50 kcal/mol
Ensemble diversity 109.20 100.24
Minimum free energy
(centroid secondary structure)
177.30 kcal/mol 171.10 kcal/mol
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